News

AcariaHealth Looks Ahead to Expanded Opportunities, Continued Service to Patients

Date: 05/20/2022

AcariaHealth, a leading national specialty pharmacy, is committed to serving patients, partners, and communities as it looks ahead to the future. AcariaHealth’s corporate parent, Centene Corporation, announced on May 5 an agreement to sell PANTHERx and Magellan Rx. To avoid any confusion in the marketplace, we want to assure our valued partners that this announcement has no impact on AcariaHealth, which has always operated separately from PANTHERx and Magellan Rx.

AcariaHealth has been a valued part of Centene since 2013 and will continue to be a wholly owned subsidiary of Centene. As an important strategic asset serving Centene members and other patients across the US, AcariaHealth provides valuable insight, expertise and access to limited distribution drugs for Centene and other specialty pharmacy customers, and Centene has no plans to make any changes to the ownership of AcariaHealth.

"As a specialty pharmacy, we are extremely well positioned to continue to thrive as an industry leader in serving our patients,” said Steve Jensen, President of AcariaHealth. "Our ability to deliver specialized therapies and patient-center care represents significant value to all our stakeholders, both internal and external. We are proud of the work we do, and we are energized to continue living our mission to improve the health of the community, one person at a time.”

AcariaHealth cultivates strong partnerships with industry professionals, including pharmaceutical manufacturers, to bring expertise and solutions to clients, especially in the management of key specialty and orphan diseases.

For patients, AcariaHealth employs a simple and focused, yet powerful strategy: provide the best care to our patients at the lowest cost to deliver the best clinical outcomes. AcariaHealth has recently invested in proprietary consumer research, digital tools, and refined communication strategies to enhance the patient experience and improve service. As a testament to this work, AcariaHealth received one of the top patient Net Promoter scores in the Managed Markets Insight and Technology Specialty Pharmacy Patient Satisfaction Survey in 2021 and 2022.